Filtered By:
Infectious Disease: Pandemics
Drug: Norvir
This page shows you your search results in order of date.
Order by Relevance | Date
Total 305 results found since Jan 2013.
Treatments for COVID-19
Annu Rev Med. 2023 Sep 18. doi: 10.1146/annurev-med-052422-020316. Online ahead of print.ABSTRACTThe treatment for COVID-19 has evolved rapidly since the start of the pandemic and now consists mainly of antiviral and immunomodulatory agents. Antivirals, such as remdesivir and nirmatrelvir-ritonavir, have proved to be most useful earlier in illness (e.g., as outpatient therapy) and for less severe disease. Immunomodulatory therapy, such as dexamethasone and interleukin-6 or Janus kinase inhibitors, are most useful in severe disease or critical illness. The role of anti-SARS-CoV-2 monoclonal antibodies has diminished because...
Source: Annual Review of Medicine - September 18, 2023 Category: General Medicine Authors: Hayden S Andrews Jonathan D Herman Rajesh T Gandhi Source Type: research
Risk Factors for the Prescription of Ineffective Antiviral Candidates for COVID-19 During the Early Pandemic Period in Korea
CONCLUSION: Ineffective antiviral agents were prescribed to a substantial number of patients during the first year of the COVID-19 pandemic in Korea. Treatment with these ineffective drugs tended to be prolonged in severely ill patients and in primary and public hospitals.PMID:37698205 | PMC:PMC10497349 | DOI:10.3346/jkms.2023.38.e280
Source: J Korean Med Sci - September 12, 2023 Category: General Medicine Authors: Eunyoung Lee Seungyeon Kim Sun Young Lee Joo Jeong Jihwan Bang Juhwan Oh Sang Do Shin Nam Joong Kim Pyoeng Gyun Choe Myoung-Don Oh Source Type: research
Pan-American Guidelines for the treatment of SARS-CoV-2/COVID-19: a joint evidence-based guideline of the Brazilian Society of Infectious Diseases (SBI) and the Pan-American Association of Infectious Diseases (API)
CONCLUSION: This guideline provides recommendations for treating patients in the Americas following the principles of evidence-based medicine. The recommendations present a set of drugs that have proven effective in the prophylaxis and treatment of COVID-19, emphasising the strong recommendation for the use of nirmatrelvir/ritonavir in outpatients as the lack of benefit from the use of hydroxychloroquine and ivermectin.PMID:37550690 | DOI:10.1186/s12941-023-00623-w
Source: Cancer Control - August 7, 2023 Category: Cancer & Oncology Authors: Alexandre Naime Barbosa Alberto Chebabo Carlos Starling Clevy P érez Cl óvis Arns Cunha David de Luna Estev ão Portela Nunes Gabriela Zambrano Juliana Carvalho Ferreira Julio Croda Maicon Falavigna Monica Maria Gomes-da-Silva Monica Thormann Sergio Cim Source Type: research
Effective Drug Candidates against Global Pandemic of Novel Corona Virus (nCoV-2019): A Probability Check through Computational Approach for Public Health Emergency
In this study, we used molecular modelling tool (molecular modelling and molecular dynamics) to identify commercially available drugs that could act on protease proteins of SARS-CoV-2. The result showed that Saquinavir, an antiretroviral medication can be used as a first line agent to treat SARS-CoV-2 infection. Saquinavir showed promising binding to the protease active site compared to other possible antiviral agents such as Nelfinavir and Lopinavir. Structural flexibility is one of the important physical properties that affect protein conformation and function and taking this account we performed molecular dynamics studi...
Source: Bioorganic Chemistry - June 26, 2023 Category: Chemistry Authors: C G Bonde J Gawad R P Bhole S C Bonde R V Chikhale Source Type: research
Reconsideration of interferon treatment for viral diseases: Lessons from SARS, MERS, and COVID-19
We present a review that summarizes current evidence of IFN treatment for COVID-19 and elaborates on other challenges in terms of the timing of IFN treatment initiation, treatment duration, and IFN type to be used. The review findings suggested that IFN acts by directly inhibiting viral replication and activating immune cell subsets. However, there is a lack of well-designed and controlled clinical trials providing firm evidence for the efficacy or safety of IFN therapy for CoVs. Additionally, critically ill patients with multiple immunosuppression-associated comorbidities may not benefit from IFN therapy, necessitating sc...
Source: International Immunopharmacology - June 22, 2023 Category: Allergy & Immunology Authors: Dan Ma Ximin Wang Min Li Chujiao Hu Lei Tang Source Type: research
Paxlovid for Treating COVID-19 Patients: A Case-Control Study From Two Hospitals in the Eastern Province of Saudi Arabia
Conclusion This study suggests that Paxlovid is highly effective in reducing the risk of severe COVID-19 or mortality. However, larger studies with better qualities are needed for a full assessment of the role of Paxlovid in COVID-19 management in Saudi Arabia.PMID:37337482 | PMC:PMC10277155 | DOI:10.7759/cureus.39234
Source: Cancer Control - June 20, 2023 Category: Cancer & Oncology Authors: Ali Alsaeed Abdullah Alkhalaf Ali Alomran Walaa Alsfyani Fadhel Alhaddad Mousa J Alhaddad Source Type: research
